With the further understanding of the synergistic mechanism of chemotherapy and immunotherapy, as well as the release of data from the clinical trial Impower150, more studies are focusing on the efficacy of immunotherapy-based combination treatment in EGFR-mutated NSCLC after EGFR-TKI resistance. Here, EGFR is linked to non-small cell lung carcinoma.